This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

ASLAN Pharmaceuticals Toekomstige groei

Future criteriumcontroles 0/6

Momenteel beschikken we niet over voldoende analisten om de groei en omzet voor ASLAN Pharmaceuticals te voorspellen.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Biotechs winstgroei	27.6%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	15 Jul 2024

Recente toekomstige groei-updates

Recent updates

ASLAN Pharma to start trial of eczema drug in patients with a previous treatment

Sep 14

ASLAN Pharmaceuticals receives DMC nod for ASLAN004 trial expansion cohort

Jan 11

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat ASLAN Pharmaceuticals onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

NasdaqCM:ASLN - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2024	N/A	-53	N/A	N/A	1
3/31/2024	12	-35	N/A	N/A	N/A
12/31/2023	12	-44	-47	-47	N/A
9/30/2023	12	-45	N/A	N/A	N/A
6/30/2023	12	-46	-59	-59	N/A
3/31/2023	N/A	-58	N/A	N/A	N/A
12/31/2022	N/A	-51	-38	-38	N/A
9/30/2022	N/A	-46	N/A	N/A	N/A
6/30/2022	N/A	-45	-36	-36	N/A
3/31/2022	N/A	-38	N/A	N/A	N/A
12/31/2021	N/A	-31	-34	-34	N/A
9/30/2021	N/A	-28	N/A	N/A	N/A
6/30/2021	N/A	-21	-21	-21	N/A
3/31/2021	N/A	-20	N/A	N/A	N/A
12/31/2020	N/A	-16	-15	-15	N/A
9/30/2020	N/A	-40	-15	-15	N/A
6/30/2020	0	-41	-20	-20	N/A
3/31/2020	N/A	-47	-24	-24	N/A
12/31/2019	3	-47	-26	-26	N/A
9/30/2019	3	-27	-29	-29	N/A
6/30/2019	3	-34	-34	-33	N/A
3/31/2019	3	-37	-47	-36	N/A
12/31/2018	N/A	-42	-63	-39	N/A
9/30/2018	N/A	-45	-63	-40	N/A
6/30/2018	N/A	-41	-61	-38	N/A
3/31/2018	N/A	-42	-52	-40	N/A
12/31/2017	N/A	-41	N/A	-35	N/A
9/30/2017	1	-33	N/A	-30	N/A
6/30/2017	12	-19	N/A	-14	N/A
3/31/2017	12	-14	N/A	-8	N/A
12/31/2016	11	-9	N/A	-6	N/A
9/30/2016	11	-7	N/A	-7	N/A
6/30/2016	0	-15	N/A	-13	N/A
3/31/2016	N/A	-15	N/A	-13	N/A
12/31/2015	N/A	-14	N/A	-11	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van ASLN boven de spaarquote ( 2.4% ) ligt.

Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van ASLN naar verwachting sneller zal groeien dan de markt US

Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van ASLN naar verwachting de komende 3 jaar aanzienlijk zal groeien.

Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van ASLN naar verwachting sneller zal groeien dan de markt US.

Hoge groei-inkomsten: Er zijn onvoldoende gegevens om te bepalen of de omzet van ASLN naar verwachting sneller zal groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van ASLN naar verwachting over 3 jaar hoog zal zijn

This company listing is no longer active

ASLAN Pharmaceuticals Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased by 8.6% to US$16.00

Price target increased to US$5.50

Price target increased to US$5.50

Price target decreased to US$5.50

Recent updates

ASLAN Pharmaceuticals Limited(NasdaqCM:ASLN) dropped from NASDAQ Composite Index

ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International Conference

New major risk - Financial position

Aslan Pharmaceuticals to Present Additional Data from Interim Analysis of Trek-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event

ASLAN Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of $5 million.

ASLAN Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of $5 million.

ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients

ASLAN Pharmaceuticals Limited Announces New Translational Data on Eblasakimab in COPD

High number of new and inexperienced directors

New major risk - Market cap size

New minor risk - Share price stability

ASLAN Pharmaceuticals Limited Presents New Data on Eblasakimab in Atopic Dermatitis and Copd Translational Models At the 7Th Dermatology Drug Development Summit

New major risk - Negative shareholders equity

ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis

ASLAN Pharmaceuticals Presents New Data from Phase 2b Study of Eblasakimab in Atopic Dermatitis in Late Breaker

New major risk - Financial position

Aslan Pharmaceuticals Limited Announces Phase 2B Treatment of Eblasakimab Monthly Dosing Shows Potential for Best-In-Class Therapy in Positive Phase 2B Study in Atopic Dermatitis

Aslan Pharmaceuticals Announces Publication in Clinical Immunology Highlighting Eblasakimab's Unique Mechanism of Action in the Treatment of Atopic Dermatitis

Price target decreased by 8.6% to US$16.00

Aslan Pharmaceuticals Announces First Patient Screened in Study of Eblasakimab in Dupilumab Experienced Atopic Dermatitis Patients

Price target increased to US$5.50

Aslan Pharmaceuticals Presents New Data on Eblasakimab in Two Late-Breaking E-Posters At the 51St Annual European Society for Dermatological Research Meeting

Price target increased to US$5.50

ASLAN Pharmaceuticals Limited Commences Clinical Program to Study Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients

ASLAN Pharma to start trial of eczema drug in patients with a previous treatment

Price target decreased to US$5.50

ASLAN Pharmaceuticals Limited Presents Late-Breaking Poster on Eblasakimab and Neuronal Itch Mechanisms at the 2022 Society for Investigative Dermatology Annual Meeting

Aslan Pharmaceuticals Announces Acceptance of Late-Breaking Abstract on Eblasakimab and Neuronal Itch Mechanisms for Poster Presentation At the 2022 Society for Investigative Dermatology Annual Meeting

ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

ASLAN Pharmaceuticals Announces Late-Breaker Presentation of Data From Eblasakimab Proof-of-Concept Study at the 2022 American Academy of Dermatology Annual Meeting

ASLAN Pharmaceuticals Limited Screens the First Patient in Its Phase 2B Dose-Ranging Clinical Study of Eblasakimab in Adults with Moderate-To-Severe Atopic Dermatitis

ASLAN Pharmaceuticals to Present Additional Data From Aslan004 Proof-Of-Concept Study at Two Upcoming Winter Dermatology Conferences

ASLAN Pharmaceuticals Announces Positive Data Conclusively Establishing Proof of Concept for ASLAN004 in Atopic Dermatitis

ASLAN Pharmaceuticals Limited announced that it expects to receive SGD 45 million in funding from K2 HealthVentures

ASLAN Pharmaceuticals Appoints Dr. Kathleen Metters as Independent Director

ASLAN Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of $60 million.

ASLAN Pharmaceuticals Limited announced that it expects to receive $17.999999 million in funding from Vivo Capital, LLC, Citadel Enterprise Americas LLC

ASLAN Pharmaceuticals Announces Executive Changes

ASLAN Pharmaceuticals Limited Announces New Data from a Study Conducted by University of Liverpool, UK

ASLAN Pharmaceuticals Opens Expansion Cohort in ASLAN004 Atopic Dermatitis Clinical Trial

ASLAN Pharmaceuticals receives DMC nod for ASLAN004 trial expansion cohort

Aslan Pharmaceuticals Limited Announces Clinical Development of Aslan004

ASLAN Pharmaceuticals to Develop ASLAN003 as Next Generation DHODH Inhibitor in Autoimmune Conditions

ASLAN Pharmaceuticals Limited Completes Enrolment in Second Cohort and Opens New Sites in US and Australia in ASLAN004 Atopic Dermatitis Study

ASLAN Pharmaceuticals Limited(GTSM:6497) dropped from S&P Global BMI Index

ASLAN Pharmaceuticals Announces Move of its Primary Listing to Nasdaq and Delisting From Taipei Exchange

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven